Diligence memo · auto-generated · as of July 2, 2026
Andson Biotech Inc.
Andson Biotech Inc. looks fair against its niche peers and is active on financing cadence.
Businessfiled
Andson Biotech Inc. operates in Biotechnology, based in ATLANTA, GA, USA. Empowering Mass Spec for Biotech and Beyond
Sub-sector tags: biotech, pharma.
Capital & rounds (filed)filed
Andson Biotech Inc. has raised $8.3M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $4.7M on 2025-10-17.
Most recent recorded round closed around 2025-10-17.
Valuation (modeled)modeled
Provath models Andson Biotech Inc. at approximately $13M (range $5.2M–$21M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.85× the median modeled value of Series A Biotechnology companies in 2025–2027 (157 peers) — value vs value, same stage and era. Within the normal band (85% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 19 months.
Last raise 8 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
The last round stepped up 1.3× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 53% of Biotechnology peers (4293 compared).
Modeled value ranks above 22% of those peers.
Closest niche peers: Acasti Pharma Inc., Edesa Biotech, Inc., 4DMedical Ltd, Arialys Therapeutics, Inc., Nuclein, LLC.
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.